| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Sep, 2024 | Jun, 2024 |
| Sales | 7,576 | 7,218 | 6,625 | 5,385 | 4,009 |
| Sales Growth | +4.96% | +8.95% | +23.03% | +34.32% | -4.34% |
| Net Income | -1,180 | -389 | -155 | 4,499 | -386 |
| Net Income Growth | -203.34% | -150.97% | -103.45% | +1,265.54% | +25.19% |
Lsl Pharma Group Inc (LSL.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
LSL Pharma Group Inc integrated pharmaceutical company specializing in the development, manufacture and distribution of high-quality natural health products and dietary supplements in solid dosage forms as well as high quality sterile ophthalmic pharmaceutical products.
Fiscal Year End Date: 12/31